| Not Yet Recruiting | Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary A NSCLC (Non-small Cell Lung Carcinoma), Stage III, EGFR Uncommon Mutations | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, Stage IV (Metastatic) Breast Cancer | Phase 1 | 2025-10-01 |
| Not Yet Recruiting | Lorlatinib in ROS1+ NSCLC With Brain Metastasis Lung Cancer (NSCLC) | Phase 2 | 2025-08-15 |
| Recruiting | Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer Gastric Cancer, Adenocarcinoma | N/A | 2025-05-01 |
| Recruiting | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer Non Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 3 | 2025-02-25 |
| Recruiting | LDRT and Chemoimmunotherapy in NPC With Liver Metastasis Nasopharyngeal Cancinoma (NPC) | Phase 2 | 2025-01-14 |
| Recruiting | Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | 2024-12-30 |
| Recruiting | Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(M HR+ Breast Cancer | — | 2024-12-05 |
| Not Yet Recruiting | Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer Advanced Gastric Cancer | N/A | 2024-08-25 |
| Not Yet Recruiting | Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With Melanoma | Phase 2 | 2024-05-15 |
| Recruiting | Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment Hepatocellular Carcinoma | Phase 2 | 2024-05-15 |
| Recruiting | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy Triple Negative Breast Neoplasms | Phase 2 | 2024-03-29 |
| Active Not Recruiting | Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer Extensive-stage Small Cell Lung Cancer (ES-SCLC) | — | 2024-02-05 |
| Recruiting | Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma, Herpesvirus 4, Human | — | 2024-01-11 |
| Recruiting | Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer Gastric Cancer | — | 2024-01-01 |
| Recruiting | 18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors Cancer, FAP | — | 2024-01-01 |
| Unknown | Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer Colorectal Cancer | Phase 2 | 2023-10-01 |
| Not Yet Recruiting | A Real-world Study of Inetetamab for First-line Treatment of MBC Breast Cancer, Real-world Study | — | 2023-09-01 |
| Unknown | Clinical Study on Nutrition Intervention in Patients With Esophageal and Gastric Cancer Treated With Chemother Nutrition Aspect of Cancer | N/A | 2023-08-30 |
| Recruiting | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC Carcinoma, Non-Small-Cell Lung | Phase 2 | 2023-06-14 |
| Unknown | Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer HR+/HER2- Breast Cancer | Phase 2 | 2023-02-07 |
| Recruiting | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine | Phase 1 / Phase 2 | 2023-01-01 |
| Recruiting | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA I Metastatic Breast Cancer, Drug Resistance, Hormone Receptor-Positive Breast Cancer | — | 2023-01-01 |
| Recruiting | Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MB Breast Cancer, Endocrine Therapy, CDK4/6 Inhibitors | — | 2023-01-01 |
| Unknown | AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer Ovarian Cancer | Phase 2 | 2022-11-25 |
| Unknown | Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer HER2-positive Breast Cancer | — | 2022-10-01 |
| Unknown | Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors Non Small Cell Lung Cancer | Phase 2 | 2022-06-12 |
| Unknown | A Study of Carilizumab Combined With Concurrent Chemoradiotherapy Cervical Cancer | Phase 2 | 2021-12-01 |
| Unknown | Research on Optimization and Evaluation of Oral Cancer Screening Methods Oral Cancer | EARLY_Phase 1 | 2021-06-01 |
| Unknown | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer Cervical Cancer | Phase 2 | 2021-05-20 |
| Unknown | A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Esophageal Squamous Cell Carcinoma | Phase 2 | 2021-03-01 |
| Unknown | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoin Hepatocellular Carcinoma, Immune Checkpoint Inhibitors | Phase 2 | 2021-02-03 |
| Completed | Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of P Small Cell Lung Cancer | Phase 2 | 2021-01-30 |
| Unknown | Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head Head and Neck Cancer, Squamous Cell Carcinoma | Phase 2 | 2021-01-20 |
| Completed | Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Col Metastatic Colorectal Adenocarcinoma | — | 2020-11-01 |
| Completed | Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer Metastatic Breast Cancer | Phase 2 | 2020-10-09 |
| Unknown | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung A Adenocarcinoma of the Lung | Phase 2 | 2020-08-26 |
| Unknown | Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma Immune Checkpoint Inhibitor, Chemotherapy Effect, Epigenetic Disorder | Phase 2 | 2020-06-26 |
| Completed | Real World Study on the Efficacy and Safety of Anti-HER2 Therapy Breast Neoplasms, HER2-positive Breast Cancer | — | 2020-06-01 |
| Unknown | Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer Metastatic Breast Cancer | Phase 2 | 2019-11-06 |
| Unknown | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Recurrent | Phase 2 | 2019-08-20 |
| Completed | Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer Metastatic Colorectal Adenocarcinoma | — | 2019-07-01 |
| Completed | Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC Metastatic Colorectal Adenocarcinoma | — | 2019-07-01 |
| Recruiting | Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients Breast Neoplasms, Neoplastic Cells, Circulating, Chemotherapy Effect | — | 2019-03-01 |
| Unknown | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and U Advanced Non Small Cell Lung Cancer, Uterine Cancer, Soft Tissue Sarcoma | Phase 2 | 2019-01-30 |
| Unknown | A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer Ovarian Cancer | Phase 1 | 2019-01-14 |
| Completed | Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer Colorectal Cancer | — | 2019-01-01 |
| Unknown | Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer Non-small Cell Lung Cancer | Phase 2 | 2018-10-15 |
| Unknown | Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovari Ovarian Cancer | Phase 3 | 2017-08-01 |
| Completed | Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer Metastatic Breast Cancer, Circulating Tumor DNA, Gene Abnormality | — | 2016-12-01 |
| Completed | Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer Metastatic Breast Cancer, Circulating Tumor DNA, Gene Abnormality | — | 2016-12-01 |
| Unknown | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage Lymphoma | Phase 2 | 2016-09-01 |